



II12

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	09/903,993	
			Filing Date	07/13/2003	
			First Named Inventor	Nilsson	
			Art Unit	1636	
			Examiner Name	Sullivan	
Sheet	1	of	5	Attorney Docket Number	USF-T147X

RECEIVED  
MAY 20 2003  
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
AS	U1	US- 5,276,059	01-04-1994	Caughney et al.	All
	U2	US- 5,297,562	03-29-1994	Potter	All
	U3	US- 5,429,947	07-04-1995	Merrill et al.	All
	U4	US- 5,434,170	07-18-1995	Andrulis, Jr.	All
	U5	US- 5,449,604	09-12-1995	Schellenberg et al.	All
	U6	US- 5,506,097	04-09-1996	Potter et al.	All
	U7	US- 5,535,760	07-16-1996	Potter	All
	U8	US- 5,571,671	11-05-1996	Potter	All
	U9	US- 5,705,401	01-06-1998	Masters et al.	All
	U10	US- 5,731,284	03-24-1998	Williams	All
	U11	US- 5,773,220	06-30-1998	DeKosky et al.	All
	U12	US- 5,753,624	05-19-1998	McMichael et al.	All
	U13	US- 5,817,626	10-06-1998	Findeis et al.	All
	U14	US- 5,830,670	11-03-1998	De la Monte et al.	All
	U15	US- 5,849,560	12-15-1998	Abraham	All
	U16	US- 5,854,215	12-29-1998	Findeis et al.	All
	U17	US- 5,958,883	09-28-1999	Snow	All
	U18	US- 5,981,208	11-09-1999	Tamburini et al.	All
	U19	US- 5,986,054	11-16-1999	St. George-Hyslop et al.	All
	U20	US- 6,043,283	03-28-2000	Giulian	All

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
AS	F1	PCT- WO 94/24266	10-27-1994	Board of Trustees of the University of Illinois	All	
	F2					
	F3					
	F4					
	F5					
	F6					
	F7					
	F8					
	F9					
	F10					

Examiner Signature		Date Considered	9/23/03
--------------------	-------------------------------------------------------------------------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (10-01)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Complete if Known	
Application Number	09/903,993
Filing Date	07/13/2001
First Named Inventor	Nilsson
Group Art Unit	1636
Examiner Name	Sullivan
Attorney Docket Number	USF-T147X

Sheet 2 of 5

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
AS	R1	ABRHAM, $\alpha_1$ -Antichymotrypsin is associated solely with amyloid deposits containing the $\beta$ -protein. Amyloid and Cell Localization of $\alpha_1$ -Antichymotrypsin, Neurobiology of Aging, June 13, 1989, Vol.11, 123-129	
AS	R2	ABRAHAM, Immunochemical identification of the serine protease inhibitor $\alpha_1$ -Antichymotrypsin in the brain amyloid deposits of Alzheimer's disease, Cell, Feb. 26, 1988 Vol. 52, 487-501	
AS	R3	AKIYAMA, Inflammation and Alzheimer's disease, Neurobiology of Aging 21, Jan. 17, 2000, 383-421	
	R4	BALES, Apolipoprotein E is essential for amyloid deposition in the APP <sup>V717F</sup> transgenic mouse model of Alzheimer's disease, PNAS, Dec. 21, 1999, Vol. 96 (26) 15233-15238	
	R5	BALES, Neuroinflammation and Alzheimer's disease: critical roles for cytokine/A $\beta$ -induced glial activation, NF- $\kappa$ B, and apolipoprotein E, Neurobiology of Aging 21, March 20, 2000, 427-432	
	R6	BALES, Lack of apolipoprotein E dramatically reduces amyloid $\beta$ -peptide deposition, Nature Genetics, Nov. 1997, vol. 17 263-264	
	R7	BULLIDO, A polymorphism in the regulatory region of APOE associated with risk of Alzheimer's dementia, nature Genetics, Jan.-1998, vol. 18 69-71	
	R8	DAS, Expression of the Alzheimer Amyloid-Promoting factor Antichymotrypsin induces in human astrocytes by IL-1, Neuron, Feb. 1995, Vol. 14 447-456	
	R9	DU, Association of an interleukin 1 $\alpha$ polymorphism with Alzheimer's disease, Neurology, Aug. 2000, vol. 55 480-483	
	R10	EVANS, Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: Implications for the pathogenesis and treatment of Alzheimer disease, Proc. Natl. Acad.Sci., Jan. 1995, Vol. 92 763-767	
	R11	FRASER, $\alpha_1$ -Antichymotrypsin binding to Alzheimer A $\beta$ peptides is sequence specific and induces fibril disaggregation in vitro, Journal of Neurochemistry, 1993, Vol. 61 (1) 298-305	
	R12	GAMES, Alzheimer-type neuropathology in transgenic mice overexpressing V717F $\beta$ -amyloid precursor protein, Nature, Feb. 9, 1995, Vol. 373 (9), 523-526	
AS	R13	GRIFFIN, Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease, Proc. Natl. Acad. Sci., Oct. 1989, vol. 86 7611-7615	

Examiner Signature		Date Considered	9/23/03
--------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC20231.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449B/PTO</b> <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/903,993
				Filing Date	07/13/2001
				First Named Inventor	Nilsson
				Group Art Unit	1636
				Examiner Name	Sullivan
				Attorney Docket Number	USF-T147X
Sheet	3	of	5		


NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
DS	R1	GRIMALDI, Association of early-onset Alzheimer's Disease with an Interleukin-1 $\alpha$ gene polymorphism, Ann Neurol 2000;47:361-365	
	R2	HAINES, No genetic effect of $\alpha_1$ -Antichymotrypsin in Alzheimer's disease, Genomics, 1996, vol. 33 53-56	
	R3	HILL, Accelerated evolution in the reactive centre regions of serine protease inhibitors, Nature, March 5, 1987, Vol. 326 96-99	
	R4	HOLTZMAN, Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease, PNAS, Jan. 6, 2000, 1-6	
	R5	HUGHES, $\alpha_2$ -macroglobulin associates with $\beta$ -amyloid peptide and prevents fibril formulation, Proc. Natl. Acad. Sci., March 1998, Vol. 95 3275-3280	
	R6	HYMAN, Quantitative analysis of senile plaques in Alzheimer disease: Observation of log-normal size distribution and molecular epidemiology of differences associated with apolipoprotein E genotype and trisomy 21 (Down syndrome), Proc. Natl. Acad. Sci., April 1995, Vol. 92, 3586-3590	
	R7	INGLIS, The murine Spi-2 proteinase inhibitor locus: a multigene family with a hypervariable reactive site domain, The EMBO Journal, 1991, Vol. 10 (2), 255-261	
	R8	JANCAUSKIENE, Alzheimer's peptide A $\beta_{1-42}$ binds to two $\beta$ -sheets of $\alpha_1$ -Antichymotrypsin and transforms it from inhibitor to substrate, The Journal of biological chemistry, Oct. 23, 1998, Vol. 273 (43) 28360-28364	
	R9	ERIKSSON, $\alpha_1$ -Antichymotrypsin regulates Alzheimer $\beta$ -amyloid peptide fibril formulation, Proc. Natl. Acad. Sci., March 1995, Vol. 92, 2313-2317	
	R10	KAMBOH, APOE*4-associated Alzheimer's disease risk is modified by $\alpha_1$ -Antichymotrypsin polymorphism, Nature Genetics, Aug. 1995, Vol. 10 486-488	
	R11	KOO, Developmental expression of $\alpha_1$ -Antichymotrypsin in brain may be related to Astrogliosis, Neurobiology of Aging, 1991, Vol.12 495-501	
	R12	MA, Alzheimer A $\beta$ neurotoxicity: promotion by Antichymotrypsin, ApoE4; inhibition by A $\beta$ -related peptides, Neurobiology of Aging, 1996, Vol.17 (5) 773-780	
DS	R13	MA, Amyloid-associated proteins $\alpha_1$ -Antichymotrypsin and apolipoprotein E promote assembly of Alzheimer $\beta$ -protein into filaments, Nature, Nov. 1994, Vol 372 (3) 92-93	

Examiner Signature		Date Considered	9/23/04
--------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449B/PTO</b> <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	09/903,993
		Filing Date	07/13/2001
		First Named Inventor	Nilsson
		Group Art Unit	1636
		Examiner Name	Sullivan
Attorney Docket Number	USF-T147X		
Sheet	4	of	5

RECEIVED  
MAY 20 2003  
TECH CENTER 1600/2000

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
AS	R1	MUCKE, Astroglial expression of human $\alpha_1$ -Antichymotrypsin enhances Alzheimer-like pathology in amyloid protein precursor transgenic mice, American Journal of Pathology, Dec. 2000, Vol. 157 (6), 2003-2009	
	R2	MULLER, Lack of association between $\alpha_1$ -Antichymotrypsin polymorphism, Alzheimer's disease, and allele E4 of apolipoprotein E, Neurology, Dec. 1996, Vol.47 1575-1577	
	R3	NACMIAS, Implication of $\alpha_1$ -Antichymotrypsin polymorphism in familial Alzheimer's disease, Neuroscience Letters, 1998, Vol. 244 85-88	
	R4	NAKATANI, An RNA polymerase II promoter containing sequences upstream and downstream from the RNA startpoint that direct initiation of transcription from the same site, Proc. Natl. Acad. Sci., June 1990, Vol. 87, 4289-4293	
	R5	NICOLL, Association of Interleukin-1 gene polymorphisms with Alzheimer's disease, Ann Neurol 2000; 47:365-368	
	R6	NILSSON, $\alpha_1$ -Antichymotrypsin promotes $\beta$ -sheet amyloid plaque deposition in a transgenic mouse model of Alzheimer's disease, The Journal of Neuroscience, March 1, 2001, Vol. 21 (5): 1444-1451	
	R7	NILSSON, The essential role of inflammation and induced gene expression in the pathogenic pathway of Alzheimer's disease, Frontiers in Bioscience, April 16, 1998, Vol. 3: 436-446	
	R8	PASTERNAK, Astrocytes in Alzheimer's disease gray matter express $\alpha_1$ -Antichymotrypsin mRNA, American Journal of Pathology, Nov. 1989, Vol. 135 (5):827-834	
	R9	POTTER, The involvement of proteases, protease inhibitors, and an Acute Phase Response in Alzheimer's disease, Annals of the New York Academy of Sciences, Dec. 31, 1992, Vol. 674: 161-173	
	R10	POTTER, The potential of BACE inhibitors for Alzheimer's therapy, Nature Biotechnology, Feb. 2000, Vol. 18:125-126	
	R11	REBECK, Apolipoprotein E in sporadic Alzheimer's disease: Allelic Variation and Receptor Interactions, Neuron, Oct. 1993, Vol. 11: 575-580	
	R12	ROGERS, Translation of the Alzheimer amyloid precursor protein mRNA is up-regulated by Interleukin-1 through 5'-untranslated region sequences, The Journal of Biological Chemistry, March 5, 1999, Vol. 274 (10): 6421-6431	
BS	R13	SANAN, Apolipoprotein E associates with $\beta$ amyloid peptide of Alzheimer's disease to form novel monofibrils, The American Society for Clinical Investigation, Inc, Aug. 1994, Vol. 94: 860-869	

Examiner Signature		Date Considered	9/25/03
--------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
Application Number		09/903,993			
Filing Date		07/13/2001			
First Named Inventor		Nilsson			
Group Art Unit		1636			
Examiner Name		Sullivan			
Attorney Docket Number		USF-T147X			
Sheet	5	of	5		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
DP	R1	SARID, Identification of a cis-acting positive regulatory element of the glial fibrillary acidic protein gene, Journal of neuroscience Research, 1991, Vol. 28:217-228	
	R2	SCHMECHEL, Increased amyloid $\beta$ -peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease, Proc. Natl. Acad. Sci., Oct. 1993, Vol. 90: 9649-9653	
	R3	SHENG, S100 $\beta$ protein expression in Alzheimer disease: potential role in the pathogenesis of Neuritic plaques, Journal of Neuroscience Research, 1994, Vol. 39:000-000	
	R4	TALBOT, Polymorphism in AACT gene may lower age of onset of Alzheimer's disease, Neuroreport, Jan. 1996, Vol. 7 (2):534-536	
	R5	SPELLANTINI, Tau protein pathology in neurodegenerative diseases, TINS, 1998, Vol. 21 (10):428-432	
	R6	WISNIEWSKI, Acceleration of Alzheimer's Fibril formation by apolipoprotein E in Vitro, American Journal of Pathology, nov. 1994, Vol. 145 (5):1030-1035	
	R7	YOSHIIWA, $\alpha_1$ -Antichymotrypsin as a risk modifier for late-onset Alzheimer's disease in Japanese apolipoprotein E E4 Allele carriers, Ann Neurol, 1997, Vol. 42:115-117	
	R8	WISNIEWSKI, Apolipoprotein E: A pathological chaperone protein in patients with cerebral and systemic amyloid, Neuroscience Letters, 1992, Vol. 135: 235-238	
	R9	YAMADA, Association of $\alpha_1$ -Antichymotrypsin polymorphism with cerebral amyloid angiopathy, Ann Neurol, 1998, Vol. 44:129-131	
	R10	YAMIN, Metalloendopeptidase EC 3.4.24.15 is necessary for Alzheimer's amyloid- $\beta$ peptide degradation, The Journal of Biological Chemistry, June 25, 1999, Vol. 274 (26):18777-18784	
	R11	JANCAUSKIENE, A specific structural interaction of Alzheimer's peptide A $\beta_{1-42}$ with $\alpha_1$ -antichymotrypsin, Nat. Struct. Biol., 1996, Vol 3(8):668-671.	
DS	R12	McGEER, Anti-inflammatory drugs and Alzheimer disease, The Lancet, 1990, 335:1037.	
	R13		

Examiner Signature		Date Considered	9/23/03
--------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.